Moving toward genetic profiling in patient care: the scope and rationale of pharmacogenetic/ecogenetic investigation.

The topic of genetic profiling in patient care was recently reviewed in Nature Biotechnology under the title “Laying the foundations for personalised medicines” ([Marshall, 1997][1]). The prevailing principle of gathering statistical information about the general patient population and then

[1]  G. Aithal,et al.  Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications , 1999, The Lancet.

[2]  L. Bertilsson,et al.  Polymorphic Drug Oxidation , 1996 .

[3]  M. Ingelman-Sundberg,et al.  Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population , 1992, Clinical pharmacology and therapeutics.

[4]  M. Ingelman-Sundberg,et al.  Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[5]  M. Eichelbaum,et al.  Proceedings: N-oxidation of sparteine in man and its interindividual differences. , 1975, Naunyn-Schmiedeberg's archives of pharmacology.

[6]  U. Meyer,et al.  Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification , 1990, The Lancet.

[7]  M. Dahl,et al.  Pharmacogenetic methods as a complement to therapeutic monitoring of antidepressants and neuroleptics. , 2000, Therapeutic drug monitoring.

[8]  V. McKusick,et al.  Genetic Control of Isoniazid Metabolism in Man , 1960, British medical journal.

[9]  L. Bertilsson,et al.  Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamics of tolterodine , 1998, Clinical pharmacology and therapeutics.

[10]  L. Bertilsson,et al.  Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S‐mephenytoin , 1992, Clinical pharmacology and therapeutics.

[11]  L. Bertilsson,et al.  Clinical pharmacology of antidepressant drugs: pharmacogenetics. , 1984, Advances in biochemical psychopharmacology.

[12]  M. Ingelman-Sundberg,et al.  Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine , 1993, The Lancet.

[13]  L. Bertilsson,et al.  10‐hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes , 1998, Clinical pharmacology and therapeutics.

[14]  C. Halldin,et al.  D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. , 1995, The American journal of psychiatry.

[15]  L. Bertilsson,et al.  Tolterodine does not affect the human in vivo metabolism of the probe drugs caffeine, debrisoquine and omeprazole. , 1999, British journal of clinical pharmacology.

[16]  M. Ingelman-Sundberg,et al.  Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. , 1995, The Journal of pharmacology and experimental therapeutics.

[17]  J. Idle,et al.  POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN , 1977, The Lancet.

[18]  M. Ingelman-Sundberg,et al.  Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. , 1999, Trends in pharmacological sciences.

[19]  C. Alm,et al.  Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. , 1992, Therapeutic drug monitoring.

[20]  M. Eichelbaum,et al.  Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. , 1991, DNA and cell biology.

[21]  J. Lindsten,et al.  A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin , 1985, Clinical pharmacology and therapeutics.

[22]  L. Bertilsson,et al.  Interphenotype differences in disposition and effect on gastrin levels of omeprazole--suitability of omeprazole as a probe for CYP2C19. , 1995, British journal of clinical pharmacology.

[23]  A. Marshall.  Laying the foundations for personalized medicines , 1998, Nature Biotechnology.